|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Jemal A, Sung H, Kelly K, Soerjomataram I
and Bray F: The Cancer Atlas, Fourth Edition. American Cancer
Society; Atlanta (GA), USA: pp. 1–5. 2025
|
|
3
|
Oncology Society of Chinese Medical
Association, . Chinese Medical Association guideline for clinical
diagnosis and treatment of lung cancer (2024 edition). Zhonghua Yi
Xue Za Zhi. 104:3175–3213. 2024.(In Chinese). PubMed/NCBI
|
|
4
|
Luo G, Zhang Y, Rumgay H, Morgan E,
Langselius O, Vignat J, Colombet M and Bray F: Estimated worldwide
variation and trends in incidence of lung cancer by histological
subtype in 2022 and over time: A population-based study. Lancet
Respir Med. 13:348–363. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE Collaborative Group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anile M, Diso D, Mantovani S, Patella M,
Russo E, Carillo C, Pecoraro Y, Onorati I, De Giacomo T, Rendina EA
and Venuta F: Uniportal video assisted thoracoscopic lobectomy:
Going directly from open surgery to a single port approach. J
Thorac Dis. 6 (Suppl 6):S641–S643. 2014.PubMed/NCBI
|
|
8
|
Liu L, Yan Y, Wang Y, Li Z, Yang L, Yu K
and Zhao Z: Comparative efficacy and safety of first-line
PD-1/PD-L1 inhibitors in immunotherapy for non-small cell lung
cancer: A network meta-analysis. Oncol Lett. 29:1572025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive
Non-Small-Cell Lung Cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hellmann MD, Paz-Ares L, Bernabe Caro R,
Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A,
Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus Ipilimumab
in Advanced Non-Small-Cell Lung Cancer. N Engl J Med.
381:2020–2031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaft JE, Oezkan F, Kris MG, Bunn PA,
Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, et
al: Neoadjuvant atezolizumab for resectable non-small cell lung
cancer: An open-label, single-arm phase II trial. Nat Med.
28:2155–2161. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forde PM, Chaft JE, Smith KN, Anagnostou
V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR,
Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung
cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spicer JD, Garassino MC, Wakelee H,
Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, et
al: Neoadjuvant pembrolizumab plus chemotherapy followed by
adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone
in patients with early-stage non-small-cell lung cancer
(KEYNOTE-671): A randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet. 404:1240–1252. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heymach JV, Harpole D, Mitsudomi T, Taube
JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, et
al: Perioperative durvalumab for resectable Non-small-cell lung
cancer. N Engl J Med. 389:1672–1684. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Felip E, Altorki N, Zhou C, Csőszi T,
Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A,
Kenmotsu H, et al: IMpower010 Investigators. Adjuvant atezolizumab
after adjuvant chemotherapy in resected stage IB-IIIA
non-small-cell lung cancer (IMpower010): A randomised, multicentre,
open-label, phase 3 trial. Lancet. 398:1344–1357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Brien M, Paz-Ares L, Marreaud S, Dafni
U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling
M, et al: Pembrolizumab versus placebo as adjuvant therapy for
completely resected stage IB-IIIA non-small-cell lung cancer
(PEARLS/KEYNOTE-091): An interim analysis of a randomised,
triple-blind, phase 3 trial. Lancet Oncol. 23:1274–1286. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Riely GJ, Wood DE, Aisner DL, Loo BW Jr,
Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, et
al: NCCN Guidelines® insights: Non-small cell lung
cancer, version 7.2025. J Natl Compr Canc Netw. 23:354–362. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Spicer JD, Cascone T, Wynes MW, Ahn MJ,
Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, et
al: Neoadjuvant and adjuvant treatments for early stage resectable
NSCLC: Consensus recommendations from the international association
for the study of lung cancer. J Thorac Oncol. 19:1373–1414. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sorscher S: Perioperative nivolumab in
resectable lung cancer. N Engl J Med. 391:5732024.PubMed/NCBI
|
|
21
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in Non-small cell lung
cancer: A Retrospective analysis. Clin Cancer Res. 22:4585–4593.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and Meta-analysis. JAMA Oncol. 4:1721–1728. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sahin TK, Ayasun R, Rizzo A and Guven DC:
Prognostic value of Neutrophil-to-Eosinophil ratio (NER) in cancer:
A systematic review and Meta-analysis. Cancers (Basel).
16:36892024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vitale E, Rizzo A, Santa K and Jirillo E:
Associations between ‘Cancer Risk’, ‘Inflammation’ and ‘Metabolic
Syndrome’: A scoping review. Biology (Basel). 13:3522024.PubMed/NCBI
|
|
25
|
Bas O, Sahin TK, Karahan L, Rizzo A and
Guven DC: Prognostic significance of the cachexia index (CXI) in
patients with cancer: A systematic review and meta-analysis. Clin
Nutr ESPEN. 68:240–247. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizzo A, Dall'Olio FG, Altimari A, Giunchi
F and Ardizzoni A: Role of PD-L1 assessment in advanced NSCLC: Does
it still matter? Anticancer Drugs. 32:1084–1085. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rizzo A, Mollica V, Marchetti A, Nuvola G,
Rosellini M, Tassinari E, Molina-Cerrillo J, Myint ZW, Buchler T,
Monteiro FSM, et al: Adjuvant PD-1 and PD-L1 inhibitors and
Relapse-free survival in cancer patients: The MOUSEION-04 study.
Cancers (Basel). 14:41422022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Zuani M, Xue H, Park JS, Dentro SC,
Seferbekova Z, Tessier J, Curras-Alonso S, Hadjipanayis A,
Athanasiadis EI, Gerstung M, et al: Single-cell and spatial
transcriptomics analysis of non-small cell lung cancer. Nat Commun.
15:43882024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amilo D, Izuchukwu C, Sadri K, Yao HR,
Hincal E and Shehu Y: A fractional-order model for optimizing
combination therapy in heterogeneous lung cancer: Integrating
immunotherapy and targeted therapy to minimize side effects. Sci
Rep. 14:184842024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Munteanu R, Tomuleasa C, Iuga CA, Gulei D
and Ciuleanu TE: Exploring therapeutic avenues in lung cancer: The
epigenetic perspective. Cancers (Basel). 15:53942023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Y, Jiang T, Fang L, Zhang T, Kang X
and Zhou C: A randomized, doubleb linded, multicenter phase 3 study
of platinum-based chemotherapy with or without QL1706 as adjuvant
therapy in completely resected stage II–IIIb NSCLC. J Clin Oncol.
41:TPS86062023. View Article : Google Scholar
|
|
32
|
Calvo V, Domine M, Sullivan I,
Gonzalez-Larriba J, Ortega A, Bernabé R, Sala M, Campos B, De
Castro J, Martín-Martorell P, et al: A phase III clinical trial of
adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA
completely resected non-small cell lung cancer (NSCLC) patients
Nadim-adjuvant: New adjuvant trial of chemotherapy versus
chemoimmunotherapy. J Clin Oncol. 39:TPS85812021. View Article : Google Scholar
|
|
33
|
Cascone T, Spira A, Campelo R, Kim D,
Hamid O, Soo-Hoo Y, Kumar R, Grenga I and Forde P: Abstract CT124:
NeoCOAST-2: A randomized, open-label, phase 2 study of neoadjuvant
durvalumab plus novel immunotherapies and chemotherapy (CT)
followed by adjuvant durvalumab plus novel agents, in patients with
resectable non-small-cell lung cancer (NSCLC). Cancer Res.
82:CT1242022. View Article : Google Scholar
|
|
34
|
Besse B, Adam J, Cozic N, Chaput-Gras N,
Planchard D, Mezquita L, Masip J, Lavaud P, Naltet C, Gazzah A, et
al: Neoadjuvant atezolizumab (A) for resectable non-small cell lung
cancer (NSCLC): Results from the phase II PRINCEPS trial. Ann
Oncol. 31 (Suppl):S794–S795. 2020. View Article : Google Scholar
|
|
35
|
Peters S, Spigel D, Ahn M, Tsuboi M, Chaft
J, Harpole D, Goss G, Barlesi F, Abbosh C, Poole L, et al: P03.03
MERMAID-1: A Phase III study of adjuvant durvalumab plus
chemotherapy in resected NSCLC patients with MRD Post-surgery. J
Thorac Oncol. 16 (Suppl):S258–S259. 2021. View Article : Google Scholar
|
|
36
|
Spigel D, Peters S, Ahn M, Tsuboi M, Chaft
J, Harpole D, Barlesi F, Abbosh C, Mann H, May R, et al: MERMAID-2:
Phase III study of durvalumab in patients with resected, stage
II–III NSCLC who become MRD after curative-intent therapy. J Thorac
Oncol. 16 (Suppl):S745–S746. 2021. View Article : Google Scholar
|
|
37
|
Goss G, Darling GE, Westeel V, Nakagawa K,
Massuti Sureda B, Perrone F, McLachlan S-A, Kang JH, Wu Y-L,
Dingemans A-M.C..et al: LBA48 CCTG BR.31: A global, double-blind
placebo-controlled, randomized phase III study of adjuvant
durvalumab in completely resected non-small cell lung cancer
(NSCLC). Ann Oncol. 35 (Suppl):S12382024. View Article : Google Scholar
|
|
38
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Galluzzi L, Buqué A, Kepp O, Zitvogel L
and Kroemer G: Immunogenic cell death in cancer and infectious
disease. Nat Rev Immunol. 17:97–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Starzer AM, Preusser M and Berghoff AS:
Immune Escape mechanisms and therapeutic approaches in cancer: The
cancer-immunity cycle. Ther Adv Med Oncol.
14:175883592210962192022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mellman I, Chen DS, Powles T and Turley
SJ: The cancer-immunity cycle: Indication, genotype, and
immunotype. Immunity. 56:2188–2205. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chu NQ, Tan KS, Dycoco J, Adusumilli PS,
Bains MS, Bott MJ, Downey RJ, Gray KD, Huang J, Isbell JM, et al:
Determinants of successful minimally invasive surgery for
resectable non-small cell lung cancer after neoadjuvant therapy. J
Thorac Cardiovasc Surg. 169:753–762.e6. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miyoshi T and Tsuboi M: Postoperative
adjuvant therapy with molecularly targeted agents for non-small
cell lung cancer. Int J Clin Oncol. 30:210–214. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim HK, Joung JG, Choi YL, Lee SH, Park
BJ, Choi YS, Ryu D, Nam JY, Lee MS, Park WY, et al: Earlier-phased
cancer immunity cycle strongly influences cancer immunity in
operable Never-smoker lung adenocarcinoma. iScience. 23:1013862020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Karasaki T, Nagayama K, Kuwano H, Nitadori
JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y,
Kashiwabara K, et al: An immunogram for the Cancer-immunity cycle:
Towards personalized immunotherapy of lung cancer. J Thorac Oncol.
12:791–803. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pio R, Ajona D, Ortiz-Espinosa S,
Mantovani A and Lambris JD: Complementing the Cancer-immunity
cycle. Front Immunol. 10:7742019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li L, Pu H, Zhang X, Guo X, Li G and Zhang
M: Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced
non-small cell lung cancer. Crit Rev Oncol Hematol. 209:1046832025.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang MY, Jiang XM, Wang BL, Sun Y and Lu
JJ: Combination therapy with PD-1/PD-L1 blockade in non-small cell
lung cancer: Strategies and mechanisms. Pharmacol Ther.
219:1076942021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vansteenkiste J, Wauters E, Park K,
Rittmeyer A, Sandler A and Spira A: Prospects and progress of
atezolizumab in non-small cell lung cancer. Expert Opin Biol Ther.
17:781–789. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang B, Xiao H, Pu X, Zhou C, Yang D, Li
X, Wang W and Xiao Q: A real-world comparison between neoadjuvant
chemoimmunotherapy and chemotherapy alone for resectable non-small
cell lung cancer. Cancer Med. 12:274–286. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cascone T, William WN Jr, Weissferdt A,
Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L,
Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab
in operable non-small cell lung cancer: The phase 2 randomized
NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rosner S, Reuss JE, Zahurak M, Zhang J,
Zeng Z, Taube J, Anagnostou V, Smith KN, Riemer J, Illei PB, et al:
Five-year clinical outcomes after neoadjuvant nivolumab in
resectable Non-small cell lung cancer. Clin Cancer Res. 29:705–710.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yang X, Yin R and Xu L: Neoadjuvant PD-1
blockade in resectable lung cancer. N Engl J Med.
379:e142018.PubMed/NCBI
|
|
55
|
Kim SS, Cooke DT, Kidane B, Tapias LF,
Lazar JF, Awori Hayanga JW, Patel JD, Neal JW, Abazeed ME, Willers
H, et al: The society of thoracic surgeons expert consensus on the
multidisciplinary management and resectability of locally advanced
Non-small cell lung cancer. Ann Thorac Surg. 119:16–33. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang C, Chen KN, Chen Q, Wu L, Wang Q, Li
X, Ying K, Wang W, Zhao J, Liu L, et al: Neoadjuvant nivolumab plus
chemotherapy versus chemotherapy for resectable NSCLC:
Subpopulation analysis of Chinese patients in CheckMate 816. ESMO
Open. 8:1020402023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhu X, Sun L, Song N, He W, Xie B, Hu J,
Zhang J, Yang J, Dai J, Bian D, et al: Safety and effectiveness of
neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage
II–III NSCLC (LungMate 002): An open-label, single-arm, phase 2
trial. BMC Med. 20:4932022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wislez M, Mazieres J, Lavole A, Zalcman G,
Carre O, Egenod T, Caliandro R, Dubos-Arvis C, Jeannin G, Molinier
O, et al: Neoadjuvant durvalumab for resectable non-small-cell lung
cancer (NSCLC): Results from a multicenter study (IFCT-1601
IONESCO). J Immunother Cancer. 10:e0056362022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian
F, Liu H, Gu Z, Huang L, Lu Q, et al: Neoadjuvant camrelizumab plus
Platinum-based chemotherapy vs Chemotherapy alone for Chinese
patients with resectable stage IIIA or IIIB (T3N2) Non-small cell
lung cancer: The TD-FOREKNOW randomized clinical trial. JAMA Oncol.
9:1348–1355. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu SY, Dong S, Yang XN, Liao RQ, Jiang
BY, Wang Q, Ben XS, Qiao GB, Lin JT, Yan HH, et al: Neoadjuvant
nivolumab with or without platinum-doublet chemotherapy based on
PD-L1 expression in resectable NSCLC (CTONG1804): A multicenter
open-label phase II study. Signal Transduct Target Ther. 8:4422023.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shao M, Yao J, Wang Y, Zhao L, Li B, Li L,
Wu Z, Chen Z, Fan J and Qiu F: Two vs three cycles of neoadjuvant
sintilimab plus chemotherapy for resectable non-small-cell lung
cancer: NeoSCORE trial. Signal Transduct Target Ther. 8:1462023.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang X, Shao M, Yao J, Zhao L, Li L, Chen
M, Zhang Y, Liu H, Chen Z, Li B, et al: NeoSCORE II: Three vs four
cycles of neoadjuvant sintilimab + chemotherapy for squamous
non-small-cell lung cancer. Future Oncol. 20:121–129. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
National Library of Medicine, .
Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III
Driven Gene Mutation Negative Non-small Cell Lung Cancer.
https://clinicaltrials.gov/study/NCT04728724August
8–2025
|
|
64
|
Kroemer G, Galluzzi L, Kepp O and Zitvogel
L: Immunogenic cell death in cancer therapy. Annu Rev Immunol.
31:51–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hamada A, Soh J, Hata A, Nakamatsu K,
Shimokawa M, Yatabe Y, Suzuki J, Tsuboi M, Horinouchi H, Sakairi Y,
et al: Neoadjuvant concurrent Chemo-Immuno-radiation therapy
followed by surgery and adjuvant immunotherapy for resectable stage
III N2 NSCLC: Primary results from the SQUAT trial (WJOG 12119L). J
Thorac Oncol. 20:1098–1107. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jabbour SK, Lee KH, Frost N, Breder V,
Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A,
Houghton B, et al: Pembrolizumab plus concurrent chemoradiation
therapy in patients with unresectable, locally advanced, stage III
Non-small cell lung cancer: The phase 2 KEYNOTE-799 Nonrandomized
Trial. JAMA Oncol. 7:1–9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Peters S, Felip E, Dafni U, Belka C,
Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, et
al: Safety evaluation of nivolumab added concurrently to
radiotherapy in a standard first line chemo-radiotherapy regimen in
stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung
Cancer. 133:83–87. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Xu YP, Li B, Xu XL and Mao WM: Is there a
survival benefit in patients with stage IIIA (N2) Non-small cell
lung cancer receiving neoadjuvant chemotherapy and/or radiotherapy
prior to surgical resection: A systematic review and Meta-analysis.
Medicine (Baltimore). 94:e8792015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Vokes EE, Herndon JE II, Kelley MJ,
Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W,
Green MR, et al: Induction chemotherapy followed by
chemoradiotherapy compared with chemoradiotherapy alone for
regionally advanced unresectable stage III Non-small-cell lung
cancer: Cancer and Leukemia Group B. J Clin Oncol. 25:1698–704.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hino A, Muto S, Shimada Y, Hori S, Isotani
S, Nagata M and Horie S: Impact of Cisplatin-induced acute kidney
injury on Long-term renal function in patients with solid tumors.
Clin Exp Nephrol. 27:506–518. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kessler L, Koo C, Richter CP and Tan X:
Hearing loss during chemotherapy: Prevalence, mechanisms, and
protection. Am J Cancer Res. 14:4597–4632. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Spicer J, Nair S, Khattak A, Lee J, Brown
M, Meehan R, Shariati N, Deng X, Samkari A and Chaft J: The phase 3
INTerpath-002 study design: Individualized neoantigen therapy (INT)
V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab
for resected early-stage non-small-cell lung cancer (NSCLC). Cancer
Res. 84:CT281. 2024. View Article : Google Scholar
|
|
73
|
Garon EB, Lu S, Goto Y, De Marchi P,
Paz-Ares L, Spigel DR, Thomas M, Yang JC, Ardizzoni A, Barlesi F,
et al: Canakinumab as adjuvant therapy in patients with completely
resected Non-Small-cell lung cancer: Results from the CANOPY-A
Double-blind, randomized clinical trial. J Clin Oncol. 42:180–191.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chaft J, Dahlberg S, Gerber D, Oxnard G,
Malik S, Simone C, Edelman M, Heymach J, Rudin C and Ramalingam S:
Adjuvant nivolumab in resected lung cancers (ANVIL): The newest
study in the ALCHEMIST platform. J Clin Oncol. 4:352017.
|
|
75
|
National Library of Medicine, . A Study of
Tiragolumab Plus Atezolizumab Compared With Placebo Plus
Atezolizumab in Participants With Completely Resected Non-small
Cell Lung Cancer Who Have Received Adjuvant Platinum-based
Chemotherapy (SKYSCRAPER-15). https://clinicaltrials.gov/study/NCT06267001August
8–2025
|
|
76
|
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu
L, Zhang P, Zhao G, Yang F, Han G, et al: RATIONALE-315
investigators. Perioperative tislelizumab plus neoadjuvant
chemotherapy for patients with resectable non-small-cell lung
cancer (RATIONALE-315): An interim analysis of a randomised
clinical trial. Lancet Respir Med. 13:119–129. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang
W, Xing W, Chen Q, Yang L, Mei J, et al: Perioperative toripalimab
plus chemotherapy for patients with resectable Non-small cell lung
cancer: The neotorch randomized clinical trial. JAMA. 331:201–211.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Provencio M, Serna-Blasco R, Nadal E, Insa
A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, et al: Overall survival and
biomarker analysis of neoadjuvant nivolumab plus chemotherapy in
operable stage IIIA Non-Small-Cell lung cancer (NADIM phase II
trial). J Clin Oncol. 40:2924–2933. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Provencio M, Nadal E, González-Larriba JL,
Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo
V, Insa A, Ponce S, et al: Perioperative nivolumab and chemotherapy
in Stage III Non-Small-Cell lung cancer. N Engl J Med. 389:504–513.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
National Library of Medicine, .
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in
Resectable Lung Cancer. https://clinicaltrials.gov/study/NCT05116462August
8–2025
|
|
81
|
National Library of Medicine, . Phase III
Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable
Stage III NSCLC. https://clinicaltrials.gov/study/NCT06123754August
8–2025
|
|
82
|
Romero Román A, Campo-Cañaveral de la Cruz
JL, Macía I, Escobar Campuzano I, Figueroa Almánzar S, Delgado Roel
M, Gálvez Muñoz C, García Fontán EM, Muguruza Trueba I, Romero
Vielva L, et al: Outcomes of surgical resection after neoadjuvant
chemoimmunotherapy in locally advanced stage IIIA non-small-cell
lung cancer. Eur J Cardiothorac Surg. 60:81–88. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yan W, Zhong WZ, Liu YH, Chen Q, Xing W,
Zhang Q, Liu L, Ge D, Chen K, Yang F, et al: Adebrelimab (SHR-1316)
in combination with chemotherapy as perioperative treatment in
patients with resectable Stage II to III NSCLCs: An Open-label,
multicenter, phase 1b trial. J Thorac Oncol. 18:194–203. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Expert group consensus on standardized
perioperative immunotherapy for non-small cell lung cancer, .
Consensus expert group on standardized perioperative immunotherapy
for Non-small cell lung cancer: Consensus expert opinion on
standardized perioperative immunotherapy for Non-small cell lung
cancer. China J Clin Oncol. 51:1–14. 2024.
|
|
85
|
Provencio M, Nadal E, Insa A, García
Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu
D, Martínez-Martí A, et al: Perioperative chemotherapy and
nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical
outcomes from a multicentre, single-arm, phase 2 trial. Lancet
Oncol. 25:1453–1464. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
The Multidisciplinary Diagnosis and
Treatment (MDT) Committee of the Chinese Anti-Cancer Association,
the Small Cell Lung Cancer Expert Committee of the China Society of
Clinical Oncology (CSCO), the Tumor Radiotherapy Committee of the
Chinese Anti-Cancer Association, . Expert consensus on radiotherapy
combined with immunotherapy for inoperable lung cancer (2024
Edition). J Cancer Prevention Control. 31:1223–1239. 2024.
|
|
87
|
Uprety D, Roden AC and Peters S: Adjuvant
Immunotherapy should be used in patients with Non-Small cell
carcinoma with a pathologic complete response to neoadjuvant
immunotherapy. J Thorac Oncol. 20:34–38. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Phillips WJ, Camidge DR and Wheatley-Price
P: Adjuvant immunotherapy should not be used in patients with a
pathologic complete response to neoadjuvant chemoimmunotherapy. J
Thorac Oncol. 20:30–33. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Sun T, Chen Z, Wei K and Tang H: Research
progress on predictive biomarkers of immunotherapy efficacy in
Non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 27:459–465.
2024.(In Chinese). PubMed/NCBI
|
|
90
|
Chen K, Yang F, Shen H, Wang C, Li X,
Chervova O, Wu S, Qiu F, Peng D, Zhu X, et al: Individualized
tumor-informed circulating tumor DNA analysis for postoperative
monitoring of non-small cell lung cancer. Cancer Cell.
41:1749–1762.e6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Peters S, Oliner KS, L'Hernault A,
Ratcliffe M, Madison H, Lai Z, Stewart R, Mann H, Lowery C, Garon
EB, et al: Durvalumab with or without tremelimumab in combination
with chemotherapy in first-line metastatic non-small-cell lung
cancer: Outcomes by tumor mutational burden in POSEIDON. ESMO Open.
10:1050582025. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Budczies J, Kazdal D, Menzel M, Beck S,
Kluck K, Altbürger C, Schwab C, Allgäuer M, Ahadova A, Kloor M, et
al: Tumour mutational burden: Clinical utility, challenges and
emerging improvements. Nat Rev Clin Oncol. 21:725–742. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wu F, Fan J, He Y, Xiong A, Yu J, Li Y,
Zhang Y, Zhao W, Zhou F, Li W, et al: Single-cell profiling of
tumor heterogeneity and the microenvironment in advanced non-small
cell lung cancer. Nat Commun. 12:25402021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Long Y, Jin R and Li H: Mechanistic
insights into the immune biomarker of perioperative immune
checkpoint inhibitors for non-small cell lung cancer. Transl Lung
Cancer Res. 14:2821–2841. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ohara S, Suda K and Tsutani Y: Utility and
future perspectives of circulating tumor DNA analysis in Non-Small
cell lung cancer patients in the era of perioperative
Chemo-immunotherapy. Cells. 14:13122025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Derraze Y, Hashemi SMS, Ulas EB, Ziesemer
KA, Lissenberg-Witte B, Radonic T and Bahce I: Evaluating the
significance of combining PD-L1 and TILs as biomarkers in non-small
cell lung cancer patients treated with immunotherapy: A systematic
review. BJC Rep. 3:652025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Costantini A, Takam Kamga P,
Pons-Tostivint E, Fradin D, Emile JF and Giroux-Leprieur E: Soluble
PD-L1 (sPD-L1) as a biomarker of durable response and survival in
patients with advanced non-small cell lung cancer (NSCLC) treated
with first-line immune checkpoint inhibitors (ICIs). Cancer Immunol
Immunother. 74:2942025. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ready N, Hellmann MD, Awad MM, Otterson
GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M,
et al: First-line nivolumab plus ipilimumab in advanced
Non-Small-Cell lung cancer (CheckMate 568): Outcomes by programmed
death ligand 1 and tumor mutational burden as biomarkers. J Clin
Oncol. 37:992–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ready NE, Audigier-Valette C, Goldman JW,
Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F,
Bordenave S, Rijavec E, et al: First-line nivolumab plus ipilimumab
for metastatic non-small cell lung cancer, including patients with
ECOG performance status 2 and other special populations: CheckMate
817. J Immunother Cancer. 11:e0061272023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee
JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker
M, Linardou H, et al: Safety of First-Line Nivolumab Plus
Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of
CheckMate 227, CheckMate 568, and CheckMate 817. J Thorac Oncol.
8:79–92. 2023. View Article : Google Scholar
|
|
101
|
Schuler M, Cuppens K, Plönes T, Wiesweg M,
Du Pont B, Hegedus B, Köster J, Mairinger F, Darwiche K, Paschen A,
et al: Neoadjuvant nivolumab with or without relatlimab in
resectable non-small-cell lung cancer: A randomized phase 2 trial.
Nat Med. 30:1602–1611. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Aokage K, Koyama S, Kumagai S, Nomura K,
Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T,
et al: Efficacy, safety, and influence on the tumor
microenvironment of neoadjuvant pembrolizumab plus ramucirumab for
PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clin Cancer
Res. 30:5584–5592. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Passaro A, Wang J, Wang Y, Lee SH, Melosky
B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, et al:
MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and
without lazertinib in EGFR-mutant advanced NSCLC after disease
progression on osimertinib: Primary results from the phase III
MARIPOSA-2 study. Ann Oncol. 35:77–90. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Spigel DR, Reynolds C, Waterhouse D, Garon
EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, et al:
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus
Crizotinib for the First-line treatment of anaplastic lymphoma
kinase translocation-positive advanced Non-small cell lung cancer
(CheckMate 370). J Thorac Oncol. 13:682–688. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hartmaier RJ, Markovets AA, Ahn MJ,
Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, et al:
Osimertinib+ savolitinib to overcome acquired MET-mediated
resistance in epidermal growth factor Receptor-Mutated,
MET-Amplified Non-small cell lung cancer: TATTON. Cancer Discov.
13:98–113. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Roesch RM, Schnorbach J, Klotz LV, Griffo
R, Thomas M, Stenzinger A, Christopoulos P, Allgaeuer M, Schneider
M, Schuler M, et al: NeoTRACK trial: Neo adjuvant T i R agolumab, A
tezolizumab and C hemotherapy-dissection of IO-efficacy in NSCLC by
longitudinal trac K ing-protocol of a non-randomised, open-label,
single-arm, phase II study. BMJ Open. 15:e0966172025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Alsaafeen BH, Ali BR and Elkord E:
Resistance mechanisms to immune checkpoint inhibitors: Updated
insights. Mol Cancer. 24:202025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kalbasi A and Ribas A: Tumour-intrinsic
resistance to immune checkpoint blockade. Nat Rev Immunol.
20:25–39. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Said SS and Ibrahim WN: Cancer resistance
to immunotherapy: Comprehensive insights with future perspectives.
Pharmaceutics. 15:11432023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Kluger H, Barrett JC, Gainor JF, Hamid O,
Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H,
et al: Society for immunotherapy of cancer (SITC) consensus
definitions for resistance to combinations of immune checkpoint
inhibitors. J Immunother Cancer. 11:e0059212023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
He J, Huang Z, Han L, Gong Y and Xie C:
Mechanisms and management of 3rd-generation EGFR-TKI resistance in
advanced non-small cell lung cancer (Review). Int J Oncol.
59:902021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cabanos HF and Hata AN: Emerging insights
into targeted Therapy-tolerant persister cells in cancer. Cancers
(Basel). 13:26662021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wei SC, Levine JH, Cogdill AP, Zhao Y,
Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D and
Allison JP: Distinct cellular mechanisms underlie Anti-CTLA-4 and
Anti-PD-1 checkpoint blockade. Cell. 170:1120–1133.e17. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Xu M, Wang Y, Xia R, Wei Y and Wei X: Role
of the CCL2-CCR2 signalling axis in cancer: Mechanisms and
therapeutic targeting. Cell Prolif. 54:e131152021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Pienta KJ, Machiels JP, Schrijvers D,
Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA,
Takimoto C, et al: Phase 2 study of carlumab (CNTO 888), a human
monoclonal antibody against CC-chemokine ligand 2 (CCL2), in
metastatic Castration-resistant prostate cancer. Invest New Drugs.
31:760–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Noel M, O'Reilly EM, Wolpin BM, Ryan DP,
Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B,
et al: Phase 1b study of a small molecule antagonist of human
chemokine (C-C motif) receptor 2 (PF-04136309) in combination with
nab-paclitaxel/gemcitabine in first-line treatment of metastatic
pancreatic ductal adenocarcinoma. Invest New Drugs. 38:800–811.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Overman MJ, Gelsomino F, Aglietta M, Wong
M, Limon Miron ML, Leonard G, García-Alfonso P, Hill AG, Cubillo
Gracian A, Van Cutsem E, et al: Nivolumab plus relatlimab in
patients with previously treated microsatellite
instability-high/mismatch repair-deficient metastatic colorectal
cancer: The phase II CheckMate 142 study. J Immunother Cancer.
12:e0086892024. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kelly RJ, Landon BV, Zaidi AH, Singh D,
Canzoniero JV, Balan A, Hales RK, Voong KR, Battafarano RJ, Jobe
BA, et al: Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor
relatlimab in resectable esophageal/gastroesophageal junction
cancer: A phase Ib trial and ctDNA analyses. Nat Med. 30:1023–1034.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Gopal AK, Armand P, Neelapu SS, Bartlett
NL, Spurgeon SE, Kuruvilla J, Savage KJ, Leonard JP, Gelb AB, Ahmed
N, et al: Nivolumab plus relatlimab for patients with relapsed or
progressed B-cell malignancies in RELATIVITY-022. Blood Adv.
9:3383–3394. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Aggarwal V, Workman CJ and Vignali DAA:
LAG-3 as the third checkpoint inhibitor. Nat Immunol. 24:1415–1422.
2023. View Article : Google Scholar : PubMed/NCBI
|
